EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

Bernardo Sousa-Pinto, Jean Bousquet iD, Rafael José Vieira iD, Holger J Schünemann, Torsten Zuberbier iD, Antonio Bognanni iD, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski und 48 weitere

Allergy · 2026-04 · 81 (4) · 954-976

DOI: 10.1111/all.70131 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Allergy, online erschienen am 01.12.2025. Verfasst von Bernardo Sousa-Pinto und 59 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Asthma, Anti-Allergic Agents. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France, Advanced Research and Invention Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management.

Methods

The ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.

Results

Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.

Conclusion

This ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicAsthmaAnti-Allergic AgentsHumansAdministration, IntranasalPractice Guidelines as TopicQuality of LifeDisease Management

Stichwörter der Autor:innen

allergic rhinitisguidelinesintranasal antihistaminesintranasal corticosteroids

Substanzen

Anti-Allergic Agents

Autor:innen und Institutionen

  • MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
  • CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
  • ARIA (Allergic Rhinitis and Its Impact on Asthma), Montpellier, France.
  • Department of Health Research Methods, Evidence, and Impact & Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Jean Bousquet, Rafael José Vieira, Torsten Zuberbier, Antonio Bognanni, Maria Jose Torres, Mohamed H Shamji, Mário Morais-Almeida, G Walter Canonica, Leticia de Las Vecillas, Ludger Klimek, Olga Lourenço, Nikolaos G Papadopoulos, Marine Savouré, Sanna K Toppila-Salmi, Alvaro A Cruz, Mattia Giovannini, Tuomas Jartti, Miloš Jeseňák, Oliver Pfaar, Luo Zhang, Tari Haahtela, Ivan Cherrez-Ojeda, Arzu Yorgancioglu, Maryam Ali Al-Nesf

Förderung

  • ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France
  • Advanced Research and Invention Agency

Zitieren

APA

Sousa-Pinto, B., Bousquet, J., Vieira, R. J., Schünemann, H. J., Zuberbier, T., Bognanni, A., Togias, A., Samolinski, B., Valiulis, A., Williams, S., Bedbrook, A., Czarlewski, W., Torres, M. J., Shamji, M. H., Morais-Almeida, M., Canonica, G. W., Vecillas, L. L., Dykewicz, M. S., Jacomelli, C., …, & Al-Nesf, M. A. (2026). Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments. Allergy, 81(4), 954-976. https://doi.org/10.1111/all.70131

Vancouver

Sousa-Pinto B, Bousquet J, Vieira RJ, Schünemann HJ, Zuberbier T, Bognanni A, et al. Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments. Allergy. 2026;81(4):954-976. doi:10.1111/all.70131

BibTeX
@article{SousaPinto2026,
  author = {Sousa-Pinto, Bernardo and Bousquet, Jean and Vieira, Rafael José and Schünemann, Holger J and Zuberbier, Torsten and Bognanni, Antonio and Togias, Alkis and Samolinski, Boleslaw and Valiulis, Arunas and Williams, Sian and Bedbrook, Anna and Czarlewski, Wienczyslawa and Torres, Maria Jose and Shamji, Mohamed H and Morais-Almeida, Mário and Canonica, G Walter and Vecillas, Leticia de Las and Dykewicz, Mark S and Jacomelli, Cristina and Klimek, Ludger and Leemann, Lucas and Lourenço, Olga and Palamarchuk, Yuliia and Papadopoulos, Nikolaos G and Pereira, Ana Margarida and Savouré, Marine and Toppila-Salmi, Sanna K and Ventura, Maria Teresa and Yepes-Nuñez, Juan José and Cruz, Alvaro A and Ciprandi, Giorgio and Gemicioglu, Bilun and Giovannini, Mattia and Gradauskiene, Brigita and Jartti, Tuomas and Jeseňák, Miloš and Kuna, Piotr and Kvedariene, Violeta and Larenas-Linnemann, Désirée E and Latiff, Amir Ha and Mohammad, Yousser and Ohta, Ken and Mahesh, Padukudru A and Pali-Schöll, Isabella and Pfaar, Oliver and Regateiro, Frederico S and Roche, Nicolas and Taborda-Barata, Luís and Ulrik, Charlotte Suppli and Rostan, Marylin Valentin and Viegi, Giovanni and Zhang, Luo and Haahtela, Tari and Cherrez-Ojeda, Ivan and Carlos Ivancevich, Juan and Khaltaev, Nikolai and Yorgancioglu, Arzu and Abdullah, Baharudin and Al-Ahmad, Mona and Al-Nesf, Maryam Ali},
  title = {Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {4},
  pages = {954--976},
  doi = {10.1111/all.70131}
}
Kostenlos starten →